February 4, 2019 | Case study, Conference Live
How we helped track and evaluate conference performance over time across multiple international events
Our client planned to have a significant presence at key global conferences over the course of a year. Find out how we effectively monitored perceptions of their brand across different regions over time.
The challenge:
Our client was developing a portfolio for the treatment of a chronic neurodegenerative disease and planned to have a significant presence at key neuroscience conferences over the coming year. With conferences being a considerable investment, they wanted to understand:
How various aspects of their presence and presentations n(vs competitors) at each event impacted their target.
The solution:
Using our proprietary tool Conference Live, we conducted research at multiple conferences across EU and US for a year. For each event, we recruited a sample of Neurologists, Psychiatrists, and Physicians. As the aim of the research was to measure perceptions over time, we recruited new respondents for each conference to capture ‘current’ perceptions and not those with views potentially affected by participation in earlier surveys.
Before, during and after each event we used online and mobile surveys to capture perceptions around the therapy area, companies engaging in this space, and of our client as an upcoming player. This allowed for a comparative analysis and a depiction of any changes over time.
To gain insight into the key aspects of physicians’ experiences, we administered a series of in-the-moment mini-questionnaires evaluating visits to a range of exhibition stands and the main scientific presentations of the day as well as a number of smaller poster presentations.
The outputs:
By conducting research over the course of several events, our client was able to effectively monitor the awareness and knowledge of their upcoming portfolio over time and learn how this differed in each region. Furthermore, they were able to track any changes in physicians’ perceptions of them becoming a key player, with clear signals as to which had been the most pivotal presentations and papers that shaped opinion.
Real-time insights meant almost immediate feedback on the initiatives they ran at each conference including the effectiveness of papers, posters, exhibition space, and marketing messages. In addition to identifying the most successful initiatives, we were also able to provide further insight into ways in which they could improve any that were less successful at future events.
This content was provided by Inizio
Latest Content from Inizio
Pegasus, the UK’s leading independent health communications consultancy, added three awards to its 2014 portfolio at last weekend’s AMEC International Summit 2014 in Amsterdam
Brighton consultancy adds top honour to its award wins
Brighton-based independent healthcare specialist looks to add award to growing list of accolades
Top UK Healthcare Communications Consultancy Moves to Brighton
A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation...
Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.
How can pharma benefit from improved patient understanding? Welcome to a new column in which Mary Assimakopoulos, Founding Director of pharma market research specialist the Research Partnership reveals findings from...
Following a survey of 1000 Psoriatic Arthritis patients, Mary Assimakopoulos shares some of the root causes behind a late diagnosis of this debilitating illness, and the patients’ own feelings towards...
This month Mary Assimakopoulos examines some of the insights gathered while surveying 2,000 patients suffering with this often misunderstood mental illness.
Mary Assimakopoulos, reveals findings from the company’s Therapy Watch market research data, investigating patient behaviour in Crohn’s Disease and discusses how pharma can benefit from improved patient understanding
